Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Average Recommendation of “Moderate Buy” from Analysts

Posted by Brenda Bartman on Aug 24th, 2026

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $18.00.

TVRD has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. BTIG Research reduced their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Piper Sandler upgraded Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a research report on Wednesday, July 8th. Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a research report on Wednesday, July 8th. Finally, Wall Street Zen raised Tvardi Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday.

Get Our Latest Stock Analysis on Tvardi Therapeutics

Tvardi Therapeutics Stock Performance

Tvardi Therapeutics stock opened at $1.86 on Monday. The stock has a market capitalization of $24.81 million, a P/E ratio of -0.67 and a beta of 0.39. The company’s fifty day moving average price is $2.40 and its 200 day moving average price is $3.10. Tvardi Therapeutics has a 1 year low of $1.50 and a 1 year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Sell-side analysts predict that Tvardi Therapeutics will post -2.35 EPS for the current year.

Institutional Investors Weigh In On Tvardi Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TVRD. JPMorgan Chase & Co. purchased a new position in shares of Tvardi Therapeutics in the second quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics during the second quarter worth about $43,000. Headlands Technologies LLC purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $80,000. New York State Common Retirement Fund purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at about $92,000. Finally, Arax Advisory Partners grew its stake in Tvardi Therapeutics by 277.2% during the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after acquiring an additional 6,173 shares in the last quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

(Get Free Report)

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.